Navigation Links
Boehringer Ingelheim and Lilly's new oral type 2 diabetes treatment for adults, Jentadueto™ (linagliptin/metformin hydrochloride) tablets, now available in U.S. pharmacies
Date:3/7/2012

adults with type 2 diabetes.

TRADJENTA is not for people with type 1 diabetes or for people with diabetic ketoacidosis (increased ketones in the blood or urine).

It is not known if TRADJENTA is safe and effective when used with insulin.

Important Safety Information

Who should not take TRADJENTA?

Do not take TRADJENTA if you are allergic to linagliptin or any of the ingredients in TRADJENTA. 

Symptoms of a serious allergic reaction to TRADJENTA are rash, raised red patches on your skin (hives), swelling of your face, lips, and throat that may cause difficulty breathing or swallowing.  If you have any symptoms of a serious allergic reaction, stop taking TRADJENTA and call your doctor right away.

What should I tell my doctor before taking TRADJENTA?

Tell your doctor if you take other medicines that can lower your blood sugar, such as a sulfonylurea or insulin.

TRADJENTA may cause serious side effects, including low blood sugar (hypoglycemia). If you take TRADJENTA with another medicine that can cause low blood sugar, such as sulfonylurea or insulin, your risk of getting low blood sugar is higher. The dose of your sulfonylurea medicine or insulin may need to be lowered while you take TRADJENTA. 

Signs and symptoms of low blood sugar may include headache, drowsiness, weakness, dizziness, confusion, irritability, hunger, fast heartbeat, sweating, or feeling jittery.

Also tell your doctor if you take rifampin (Rifadin®, Rimactane®, Rifater®, Rifamate®), an antibiotic that is used to treat tuberculosis.

TRADJENTA may affect the way other medicines work, and other medicines may affect how TRADJENTA works.

Tell your doctor if you are pregnant or planning to become pregnant or are breast-feeding or plan to breast-feed.

Tell your doctor about all the medicines you take, including prescription and non-prescri
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
4. Boehringer Ingelheim Unveils Diabetes Pipeline
5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... SUNNYVALE, Calif. , May 22, 2013   ... today that its management is scheduled to present at ... New York on Thursday, June 6, 2013 ... live webcast of the presentation will be available online ... at  http://www.accuray.com/investors . The webcast replay of ...
(Date:5/22/2013)... Del. and MUNICH , May ... developer, manufacturer and marketer of transcatheter aortic valve implantation (TAVI) ... its first interim results of the J enaValve Eval ... I n Pa T ients with S E vere ... Paris . JUPITER is a post-market registry to ...
(Date:5/22/2013)... May 22, 2013  The Lupus Research Institute (LRI) ... advancing new treatments for lupus nephritis, a serious kidney ... patients. The conference launched a new international alliance of ... Trials Network (LNTN). More than 50 of ... came together to focus on two critical questions: 1) ...
Breaking Medicine Technology:First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 2First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 3First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 4Lupus Research Institute Hosts First International Conference to Advance New Treatments for Lupus Nephritis 2
(Date:5/22/2013)... New York, New York (PRWEB) May 22, 2013 ... a metal-on-metal version of the DePuy Pinnacle Hip Replacement ... underway in Texas Federal Court, Bernstein Liebhard LLP reports. ... Court has directed DePuy Orthopaedics to produce monitoring reports ... government into the company’s medical device marketing practices. ...
(Date:5/22/2013)... Los Angeles, California (PRWEB) May 22, 2013 ... Report article entitled “Women Have More Options for Breast Cancer ... cancer an opportunity to approach this disease in a ... surgery has been developed, women now face breast cancer ... outcome (Go to goo.gl/ARqoN). , “Before the introduction of plastic ...
(Date:5/22/2013)... University of Michigan study challenges previous research that ... , The study, a collaboration between researchers at ... looks deeper into the controversial argument over whether ... for pitchers of the same race. It found ... Jason Winfree, associate professor of sport management at ...
(Date:5/22/2013)... WEDNESDAY, May 22 (HealthDay News) -- Migraines and depression ... new research indicates the combination of the two may ... brain. , , Already aware that people with migraines ... determine if having both conditions together affected total brain ... -- isn,t alarming, study authors said, but needs further ...
(Date:5/22/2013)... Phelps Memorial Hospital Center in Sleepy ... Center for individuals who would like to be screened ... is the deadliest form of cancer for both men and ... from lung cancer than from breast, colon and prostate cancer ... survival rates. It is well established that routine mammography ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation 2Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation 3Health News:Breast Augmentation – New Option for Breast Cancer Surgeries 2Health News:U-M study challenges notion that umpires call more strikes for pitchers of same race 2Health News:Having Both Migraines, Depression May Mean Smaller Brain 2Health News:Having Both Migraines, Depression May Mean Smaller Brain 3Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 2Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 3
... -- A University of Michigan Health System laboratory study reveals ... could lead to a new treatment for those with sickle ... in this week,s early edition of the Proceedings of ... preventing the painful episodes and organ damage that are common ...
... Gordon HealthDay Reporter , TUESDAY, Nov. 1 (HealthDay ... their risk of developing cancer compared to the general population. ... cancer, according to new research. In any ... transplant is just 0.7 percent. And experts say the benefits ...
... Gardner HealthDay Reporter , TUESDAY, Nov. 1 ... disorder don,t appear to raise the risk of heart ... adults, new research shows. And if any ... Concerta does exist, the danger in absolute numbers would ...
... equation that is difficult to solve for most people, but ... transport can be an almost insurmountable task. A newly launched ... now enlisting the help of the senior citizens themselves to ... hoped that the results will lead to better urban planning. ...
... -- Women undergoing angioplasty, a procedure to unblock a clogged ... to new research. However, the study also shows ... an angioplasty than male patients. In conducting the study, ... Interventions , researchers analyzed information on almost 4,800 women and ...
... from Rhode Island Hospital examined how the perception of ... Through a web survey with embedded interventions, the researchers ... indicators of patient satisfaction, while staff reported changing or ... paper was published in the European Journal of ...
Cached Medicine News:Health News:Researchers reveal potential treatment for sickle cell disease 2Health News:Cancer Risk Doubles After Organ Transplant, Study Finds 2Health News:Cancer Risk Doubles After Organ Transplant, Study Finds 3Health News:Little Evidence of Heart Risks From ADHD Meds 2Health News:Little Evidence of Heart Risks From ADHD Meds 3Health News:Little Evidence of Heart Risks From ADHD Meds 4Health News:Senior citizens as co-researchers to improve urban planning 2Health News:Women No More Likely to Die After Angioplasty 2Health News:How staff perceptions of their roles impact patients experience in the emergency department 2Health News:How staff perceptions of their roles impact patients experience in the emergency department 3
... The Bright Starlet is the world's smallest ... instrument with a choice of handwheel or lever ... is easy-to-clean and resist common decontaminating agents. An ... of the refrigeration system and to reduce frosting ...
... ASP300 smart tissue processor features superior user ... is a fully enclosed, stand-alone system for ... This new tissue processor combines proven technology ... screen and easy to use,yet powerful software. ...
... The Leica ASP200 is an advanced ... in standard and routine histopathology applications. Proven ... interface and smart operating software are the ... operations are simplified and the software includes ...
... microtome with automatic fine/trim- feed system, ... precision cross roller bearings. For sectioning ... in biological, botany, and materials science. ... 90 mm can be accommodated. Performance, ...
Medicine Products: